Recursion and exscientia enter definitive agreement to create a global technology-enabled drug discovery leader with end-to-end capabilities

Operational complementarities expected to yield annual synergies of approximately $100 million operational complementarities expected to yield annual synergies of approximately $100 million

EXAI Ratings Summary

EXAI Quant Ranking